Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A

Vaccine

Volumn 24, Issue 19, 2006, Pages 4167-4178

  Walsh, Douglas S ^a   Gettayacamin, Montip ^a   Leitner, Wolfgang W ^b   Lyon, Jeffrey A ^c   Stewart, V Ann ^c   Marit, Gary ^a   Pichyangkul, Sathit ^a   Gosi, Panita ^a   Tongtawe, Pongsri ^a   Kester, Kent E ^c   Holland, Carolyn A ^c   Kolodny, Nelly ^c   Cohen, Joe ^d   Voss, Gerald ^d   Ballou, W Ripley ^c   Heppner Jr , D Gray ^a  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

AS02A; Circumsporozoite protein; DNA vaccine; Malaria; Prime boost; Recombinant protein; RTS,S

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; MALARIA VACCINE; PLASMID DNA; RECOMBINANT VACCINE; RTSS AS 02 A; UNCLASSIFIED DRUG; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; RTS,S AS02A VACCINE; RTS,S-AS02A VACCINE;

ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; GENE GUN; GENETIC TRANSFECTION; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALE; NONHUMAN; NUCLEOTIDE REPEAT; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RHESUS MONKEY; SKIN TEST; TANDEM REPEAT; ANIMAL; BIOLISTIC TRANSFORMATION; BIOSYNTHESIS; GENETICS; HUMAN; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MACACA; MALARIA FALCIPARUM; SAFETY;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BIOLISTICS; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SAFETY; VACCINES, DNA;

EID: 33747356806     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.02.041     Document Type: Article

References (61)

1. Snow R.W., Guerra C.A., Noor A.M., Myint H.Y., and Hay S.I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434 (2005) 214-217
2. Heppner Jr. D.G., Kester K.E., Ockenhouse C.F., Tornieporth N., Ofori O., Lyon J.A., et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23 (2005) 2243-2250
3. Ballou W.R. Malaria vaccines in development. Expert Opin Emerg Drugs 10 (2005) 489-503
4. Garcon N., Heppner D.G., and Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2 (2003) 231-238
5. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336 (1997) 86-91
6. Stoute J.A., Kester K.E., Krzych U., Wellde B.T., Hall T., White K., et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 178 (1998) 1139-1144
7. Kester K.E., McKinney D.A., Tornieporth N., Ockenhouse C.F., Heppner D.G., Hall T., et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183 (2001) 640-647
8. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (2001) 1927-1934
9. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 (2004) 1411-1420
10. Alonso P.L., Jahit Sacarlal J., Aponte J.J., Leach A., Macete E., Aide P., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 (2005) 2012-2018
11. Lalvani A., Moris P., Voss G., Pathan A.A., Kester K.E., Brookes R., et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 180 (1999) 1656-1664
12. Pinder M., Reece W.H., Plebanski M., Akinwunmi P., Flanagan K.L., Lee E.A., et al. Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia. Clin Exp Immunol 135 (2004) 286-293
13. Sun P., Schwenk R., White K., Stoute J.A., Cohen J., Ballou W.R., et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol 171 (2003) 6961-6967
14. Webster D.P., Dunachie S., Vuola J.M., Berthoud T., Keating S., Laidlaw S.M., et al. Enhanced T-cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 102 (2005) 4836-4841
15. Doolan D.L., Sedegah M., Hedstrom R.C., Hobart P., Charoenvit Y., and Hoffman S.L. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J Exp Med 183 (1996) 1739-1746
16. Hoffman S.L., Sedegah M., and Hedstrom R. Protection against malaria by immunization with a Plasmodium yoelli circumsporozoite nucleic acid vaccine. Vaccine 12 (1994) 1529-1532
17. Weiss R., Leitner W.W., Scheiblhofer S., Chen D., Bernhaupt A., Mostbock S., et al. Genetic vaccination against malaria infection by intradermal and epidermal injections of a plasmid containing the gene encoding the Plasmodium berghei circumsporozoite protein. Infect Immun 68 (2000) 5914-5919
18. Smooker P.M., Rainczuk A., Kennedy N., and Spithill T.W. DNA vaccines and their application against parasites-promise, limitations and potential solutions. Biotechnol Annu Rev 10 (2004) 189-236
19. Wang R., Richie T.L., Baraceros M.F., Rahardjo N., Gay T., Banania J.G., et al. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect Immun 73 (2005) 2863-2872
20. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9 (2003) 729-735
21. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., and Robinson H.L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene gun inoculations. Proc Natl Acad Sci USA 90 (1993) 11478-11482
22. Leitner W.W., Seguin M.C., Ballou W.R., Seitz J.P., Schultz A.M., Sheehy M.J., et al. Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J Immunol 159 (1997) 6112-6119
23. McCluskie M.J., Brazolot Millan C.L., Gramzinski R.A., Robinson H.L., Santoro J.C., Fuller J.T., et al. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med 5 (1999) 287-300
24. Bhardwaj D., Kushwaha A., Puri S.K., Herrera A., Singh N., and Chauhan V.S. DNA prime-protein boost immunization in monkeys: efficacy of a novel construct containing functional domains of Plasmodium cynomolgi CS and TRAP. FEMS Immunol Med Microbiol 39 (2003) 241-250
25. Coban C., Philipp M.T., Purcell J.E., Keister D.B., Okulate M., Martin D.S., et al. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations. Infect Immun 72 (2004) 253-259
26. Jones T.R., Narum D.L., Gozalo A.S., Aguiar J., Fuhrmann S.R., Liang H., et al. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J Infect Dis 183 (2001) 303-312
27. Rogers W.O., Baird J.K., Kumar A., Tine J.A., Weiss W., Aguiar J.C., et al. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infect Immun 69 (2001) 5565-5572
28. Walsh D.S., Looareesuwan S., Vaniganonta S., Viravan C., and Webster H.K. Cutaneous delayed-type hypersensitivity responsiveness in patients during and after Plasmodium falciparum and Plasmodium vivax infections. Clin Immunol Immunopathol 77 (1995) 89-94
29. Kamath A.T., Feng C.G., Macdonald M., Briscoe H., and Britton W.J. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 67 (1999) 1702-1707
30. Scheiblhofer S., Chen D., Weiss R., Khan F., Mostbock S., Fegeding K., et al. Removal of the circumsporozoite protein (CSP) glycosylphosphatidylinositol signal sequence from a CSP DNA vaccine enhances induction of CSP-specific Th2 type immune responses and improves protection against malaria infection. Eur J Immunol 31 (2001) 692-698
31. Raz E., Carson D., Parker S., Parr T., Abai A., Aichinger G., et al. Intradermal gene gun immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 91 (1994) 9519-9523
32. Williams R., Johnston S., Riedy M., DeVit M., McElligott S., and Sanford J. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc Natl Acad Sci 88 (1991) 2726-2730
33. Yang N., Burkholder J., Martinell B., and Mc Cabe D. In vivo and in vitro transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 87 (1990) 9568-9572
34. Kolodny N., Kitov S., Vassell M.A., Miller V.L., Ware L.A., Fegeding K., et al. Two-step chromatographic purification of recombinant Plasmodium falciparum circumsporozoite protein from Escherichia coli. J Chromatogr B: Biomed Sci Appl 762 (2001) 77-86
35. Silber A., Newman W., Reimann K.A., Hendricks E., Walsh D., and Ringler D.J. Kinetic expression of endothelial adhesion molecules and relationship to leukocyte recruitment in two cutaneous models of inflammation. Lab Invest 70 (1994) 163-175
36. Silber A., Newman W., Sasseville V.G., Pauley D., Beall D., Walsh D.G., et al. Recruitment of lymphocytes during cutaneous delayed hypersensitivity in nonhuman primates is dependent on E-selectin and vascular cell adhesion molecule 1. J Clin Invest 93 (1994) 1554-1563
37. Ringler D., Hancock W., King N., and Murphy G. Characterization of nonhuman primate epidermal and dermal dendritic cells with monoclonal antibodies. Lab Invest 56 (1987) 313-320
38. do Rosario V.E., Appiah A., Vaughan J.A., and Hollingdale M.R. Plasmodium falciparum: administration of anti-sporozoite antibodies during sporogony results in production of sporozoites which are not neutralized by human anti-circumsporozoite protein vaccine sera. Trans R Soc Trop Med Hyg 83 (1989) 305-307
39. Black C.A. Delayed-type hypersensitivity: current theories with an historic perspective. Dermatol Online J 5 (1999) 7. http://dermatology.cdlib.org/DOJvol5num1/reviews/black.html [accessed 14 January 2006]
40. Epstein J.E., Charoenvit Y., Kester K.E., Wang R., Newcomer R., Fitzpatrick S., et al. Safety, tolerability, and antibody responses in humans after sequential immunization with a Pf CSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine 22 (2004) 1592-1603
41. Epstein J.E., Gorak E.J., Charoenvit Y., Wang R., Freydberg N., Osinowo O., et al. Safety, tolerability, and lack of antibody responses after administration of a Pf CSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther 13 (2002) 1551-1560
42. Dunachie S., Walther M., Vuola J., Webster D., Keating S., Berthoud T., et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine 24 (2006) 2850-2859
43. Cho J.H., Youn J.W., and Sung Y.C. Cross-priming as a predominant mechanism for inducing CD8(+) T-cell responses in gene gun DNA immunization. J Immunol 167 (2001) 5549-5557
44. Marwick C. Exciting potential of DNA vaccines explored. JAMA 273 (1995) 1403-1404
45. McDonnell W.M., and Askari F.K. DNA vaccines. N Engl J Med 334 (1996) 42-45
46. Robinson A. DNA-based vaccines: new possibilities for disease prevention and treatment. Can Med Assoc J 152 (1995) 1629-1632
47. Gamvrellis A., Leong D., Hanley J.C., Xiang S.D., Mottram P., and Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol 82 (2004) 506-516
48. Le T.P., Coonan K.M., Hedstrom R.C., Charoenvit Y., Sedegah M., Epstein J.E., et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18 (2000) 1893-1901
49. Wang R., Epstein J., Charoenvit Y., Baraceros F.M., Rahardjo N., Gay T., et al. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. J Immunol 172 (2004) 5561-5569
50. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282 (1998) 476-480
51. Wang R., Epstein J., Baraceros F.M., Gorak E.J., Charoenvit Y., Carucci D.J., et al. Induction of CD4(+) T-cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA 98 (2001) 10817-10822
52. Gramzinski R.A., Maris D.C., Doolan D., Charoenvit Y., Obaldia N., Rossan R., et al. Malaria DNA vaccines in Aotus monkeys. Vaccine 15 (1997) 913-915
53. Rogers W.O., Weiss W.R., Kumar A., Aguiar J.C., Tine J.A., Gwadz R., et al. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infect Immun 70 (2002) 4329-4335
54. Reece W.H., Pinder M., Gothard P.K., Milligan P., Bojang K., Doherty T., et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 10 (2004) 406-410
55. Hutchings C.L., Gilbert S.C., Hill A.V., and Moore A.C. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral- and cell-mediated immunity. J Immunol 175 (2005) 599-606
56. Moore A.C., and Hill A.V. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev 199 (2004) 126-143
57. Gilbert S.C., Schneider J., Hannan C.M., Hu J.T., Plebanski M., Sinden R., et al. Enhanced CD8 T-cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20 (2002) 1039-1045
58. Bruna-Romero O., Gonzalez-Aseguinolaza G., Hafalla J.C., Tsuji M., and Nussenzweig R.S. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci USA 98 (2001) 11491-11496
59. Rodrigues E.G., Claassen J., Lee S., Wilson J.M., Nussenzweig R.S., and Tsuji M. Interferon-gamma-independent CD8+ T-cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus. Parasite Immunol 22 (2000) 157-160
60. Rodrigues E.G., Zavala F., Nussenzweig R.S., Wilson J.M., and Tsuji M. Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine 16 (1998) 1812-1817
61. Ockenhouse C.F., Sun P.F., Lanar D.E., Wellde B.T., Hall B.T., Kester K., et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 177 (1998) 1664-1673